Side-by-side · Research reference
AOD-9604vsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed10/47 cited
BFDA-ApprovedReviewed13/41 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
SQ · Abdomen · Daily fasted
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
AOD-9604
PT-141
Primary target
β3-adrenergic receptor (proposed)Ng 2008
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
No GH-axis or IGF-1 feedback
—
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
AOD-9604
PT-141
Standard dose
250–300 mcg / dayHeffernan 2001
Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily, fasted
PRN, max 8 doses / month
Lower / starter dose
150 mcg / day
1 mg (off-label)
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2008
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
8–12 weeks per cycle
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
≥45 min before sexual activity
04Side Effects & Safety
Parameter
AOD-9604
PT-141
Injection site reaction
Mild erythema
Erythema, mild pain
GI symptoms
Rare mild nausea
—
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
—
Pregnancy / OB
Avoid
Contraindicated
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
AOD-9604
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease (caution with β-receptor agonists)
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
AOD-9604
- ·Concurrent β-blocker therapy (theoretical antagonism)
- ·Pheochromocytoma
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
AOD-9604
PT-141
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen or thigh.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
29–31G, 4–8 mm insulin syringe.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
06Stack Synergy
AOD-9604
+ MOTS-c
ModerateAOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.
- AOD-9604
- 250–300 mcg SQ · morning fasted (daily)
- MOTS-c
- 5 mg SQ · 2–3× per week (pre-workout)
- Primary benefit
- Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
PT-141
— no documented stacks